Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ofloxacin
Drug ID BADD_D01598
Description A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Indications and Usage For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.
Marketing Status approved
ATC Code J01MA01; S01AE01; S02AA16
DrugBank ID DB01165
KEGG ID D00453
MeSH ID D015242
PubChem ID 4583
TTD Drug ID D03NHW
NDC Product Code 13985-602; 17478-713; 24208-410; 60505-0560; 63187-472; 63187-734; 0404-7189; 68071-2265; 68788-8195; 70756-607; 75834-119; 11980-779; 53002-1604; 53002-2604; 50090-5186; 60505-0363; 70518-2037; 71209-099; 70518-0192; 70518-3573; 59116-1820; 68788-8178; 70518-3710; 71205-420; 53069-0440; 53002-1324; 63187-184; 64980-432; 71209-097; 58032-0090; 24208-434; 68071-2254; 68071-2544; 68071-2834; 75834-112; 75834-120; 68071-3448; 68788-7693; 72189-108; 50090-1346; 63187-662; 64980-515; 63187-268; 63629-8716; 68788-8264; 68788-8449; 71209-098; 59390-140
UNII A4P49JAZ9H
Synonyms Ofloxacin | Ofloxacine | Tarivid | ORF-28489 | ORF 28489 | ORF28489 | DR-3355 | DR 3355 | DR3355 | Hoe-280 | Hoe 280 | Hoe280 | Ofloxacin Hydrochloride | Ru-43280 | Ru 43280 | Ru43280 | DL-8280 | DL 8280 | DL8280
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 82419-36-1
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tinnitus04.04.01.002; 17.04.07.0040.000083%
Torsade de pointes02.03.04.005---
Toxic epidermal necrolysis10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.0080.000167%
Tremor17.01.06.0020.000208%
Tuberculosis11.04.01.006---
Type I hypersensitivity10.01.03.0060.000167%-
Urethritis11.01.14.008; 20.07.02.001--
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.0010.000125%
Vaginal discharge21.08.02.002--
Vaginal infection11.01.10.002; 21.14.02.002--
Vascular purpura01.01.04.007; 23.06.01.008; 24.07.06.011---
Vasculitis10.02.02.006; 24.12.04.027--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred06.02.06.007; 17.17.01.0100.000408%
Visual impairment06.02.10.0130.000267%-
Vomiting07.01.07.003--
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Weight decreased13.15.01.005--
Tubulointerstitial nephritis20.05.02.0020.000083%-
Hypoacusis04.02.01.006--
Peripheral swelling02.05.04.015; 08.01.03.0530.000125%-
General physical health deterioration08.01.03.0180.000167%-
Balance disorder08.01.03.081; 17.02.02.0070.000083%-
Contusion12.01.06.001; 15.03.05.007; 23.03.11.002; 24.07.06.001--
Eyelids pruritus06.08.03.007; 23.03.12.005---
Eye oedema06.08.03.013---
Eye pruritus06.04.05.006---
Ocular discomfort06.08.03.008---
Protein urine present13.13.02.006---
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene